Deaths due to peptic ulceration can be prevented only by curing the ulcer and preventing the ulcer diathesis permanently by either medical or surgical means. Recurrence of ulcers after drug treatment is a major problem, so continuous treatment is often necessary, but there is no evidence that this decreases mortality. Surgery is the only means of permanently removing the ulcer diathesis in most patients, and subsequent mortality is low. A reasonable balance has to be achieved between the two kinds of treatment to prevent most deaths from peptic ulcer.
Introduction
We should not be complacent about peptic ulceration, which accounted for 4259 deaths in England and Wales in 1983.' Eleven thousand people die each year of carcinoma of the stomach and a similar number of carcinoma of the breast, while 5000 die of cancer of the pancreas. Thus peptic ulcer remains in the league table of major killers but with one fundamental difference from these other disorders in that some deaths from peptic ulcer are potentially preventable, whereas malignant neoplasms of the bronchus and upper gastrointestinal tract carry little hope of long term or improved survival in the foreseeable future.
Preventing deaths
How can we prevent deaths from peptic ulceration? Ninety five per cent of such deaths occur in patients over the age of 55,' the mean age at death for men being 69 Although the prevalence of peptic ulceration is declining, the mortality remains constant, and the decline in prevalence preceded the introduction of the H2 receptor antagonists. There is no evidence that the overall mortality from peptic ulceration has been influenced by these drugs.
What is the cost of long term maintenance treatment? Maintenace treatment with cimetidine (400 mg daily) would cost £1000 a decade and with ranitidine (150 mg daily) £1800. 22 We do not know for how long such treatment would be required, but, given that stopping treatment almost inevitably leads to a recurrence of ulcer, many patients would require the drug for three, four, or even more decades. Over such a long period, with rates of recurrence of 2-5% a month being reported,'820 almost all ulcers would recur, at least temporarily, within a period of four years, thus placing a question mark over the efficacy of long term maintenance treatment. Ideally we should strive for a complete cure of the ulcer diathesis, for even if the ulcer is present for only some of the time this renders the patients at risk of potentially fatal complications with increasing age. Therefore we must express more concern towards rates of relapse than towards the rate of spontaneous or drug induced healing, which is almost inevitably intermittent. To T V TAYLOR, MD, CHM, consultant gastrointestinal surgeon mortality some 50 times as great. Ninety five per cent of deaths from complications of ulcer occur in patients over the age of 55. Those occurring after elective surgery, however, would generally be in younger people and thus "front load" the mortality equation and increase the loss in life years.
Gear compared highly selective vagotomy with long term maintenance treatment with cimetidine over one to four years in 44 patients. 30 The rate of recurrence was 10% after highly selective vagotomy and 54% in the group given cimetidine. Andersen and his colleagues compared highly selective vagotomy performed for recurrence of ulcer after an eight week course of cimetidine with repeated eight week courses of the drug on relapse.3'32 After three years the rate of cumulative operations was 74% in the "full dose, stop" group and 60% in the group given repeated cimetidine. When nocturnal maintenance treatment was used after healing and was continued the proportion coming to surgery for recurrence in the three years was still 30%.
According to the Registrar General's figures, about 24000 new cases of peptic ulcer occur each year, though this is undoubtedly an underestimate. Assuming that the ulcer diathesis of these patients remains with them between the ages of 50 and 60, bleeding would be expected in 6000 of these patients and perforation in 2400 during that decade.24 There would thus be 600 deaths after haemorrhage and 240 deaths after perforation. Of those who bleed, 4000 would be expected to rebleed, accounting for a further 400 deaths. Reperforation after simple oversewing of the ulcer would occur in 240 patients accounting for a further 24 deaths. The process could be continued, but taken thus far 1264 deaths would have occurred from peptic ulcer. Looked at in this way the figures account for only 29% of all deaths from ulcer, but, as I stated, the Registrar General's figures are a gross underestimate.
What if these 24 000 patients had all presented with symptoms of peptic ulcer before their complications? If they were submitted to elective surgery before the age of 50 (either highly selective vagotomy or anterior lesser curve seromyotomy with posterior truncal vagotomy with an operative mortality of 0/2%) 48 deaths would occur postoperatively. If the prevalence of recurrent ulcer was as high as 10% after surgery to preserve the pylorus and these recurrences were treated by elective truncal vagotomy and antrectomy, with a mortality of 1%, there would be a further 24 deaths and a further 14 ulcers. Thus 72 deaths would occur if all 24000 patients underwent elective surgery, compared with 1264 if they did not; moreover most of the surgical group would have their ulcers permanentlv cured. Thus it would seem, using these approximations based on the figures available, that 94% of patients who die from ulcers might be saved by elective surgery before the development of complications of peptic ulceration.
Achieving a balance
The accuracy of these figures will clearly be questioned, for it is impossible to know the exact prevalence of the disorder. Additionally, some patients will develop bleeding or perforation before their ulcer has become manifest clinically. These patients would be expected to have a higher mortality after operation, but if they are treated before the age of 50 this mortality is low. The ulcer diathesis tends, however, to stay with people, and the older they become the more likely they are to suffer a fatal complication. A reasonable balance has to be achieved, as there would be no justification for operating on all chronic peptic ulcers on diagnosis. In my own practice the last 100 patients who underwent elective surgery for ulcer had had a mean duration of symptoms before operation of 10 years, but most were under the age of 50. Perhaps elective surgery should be recommended for those whose ulcer returns after two separate two month courses of an H, receptor antagonist; those who have repeatedly relapsed at an early date after stopping treatment; and those whose symptoms become resistant to H2 receptor antagonists. The fact remains that surgery offers the only hope of permanently curing the ulcer diathesis and thus preventing deaths from ulcers. Such a policy has the potential to prevent most deaths from peptic ulcer.
The effectiveness of tamoxifen in suppressing metastases from carcinoma of the breast suggests that it is logical to treat patients who have had local lumpectomy or more radical breast surgery with tamoxifen as a routine. Is this a reasonable approach to treatment?
This so called adjuvant treatment of breast carcinoma with endocrine therapy is already now under way, and several trials are in progress, most of which are based on tamoxifen. A large multicentre randomised trial in the United Kingdom is showing a considerable survival advantage for patients treated with tamoxifen compared with no treatment controls. Interestingly, this advantage for survival is seen in both premenopausal and postmenopausal patients, and currently it would appear that it is effective whether the primary tumour has shown oestrogen receptor positivity or no receptors present. The great advantage of tamoxifen over chemotherapy is its lack of side effects and toxicity, and this would appear to be a promising form of adjuvant therapy. Nevertheless, I think caution is required, as the final results in breast cancer cannot be determined until many years have elapsed. For a critical review of controversies in the medical management of breast cancer, I would recommend Smith's article in the Postgraduate Medical Journal.' A further useful reference appeared in the Lancet.2-j MALPAS, professor of medical oncology, London.
